Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleDrug Discovery and Translational Medicine

Beneficial Effect of the Soluble Guanylyl Cyclase Stimulator BAY 41-2272 on Impaired Penile Erection in db/db−/− Type II Diabetic and Obese Mice

Kenia Pedrosa Nunes, Cleber E. Teixeira, Fernanda B. M. Priviero, Haroldo A. Toque and R. Clinton Webb
Journal of Pharmacology and Experimental Therapeutics May 2015, 353 (2) 330-339; DOI: https://doi.org/10.1124/jpet.114.220970
Kenia Pedrosa Nunes
Department of Cell and Regenerative Biology, University of Wisconsin, Madison, Wisconsin (K.P.N.); Laboratory of Multidisciplinary Research, Universidade São Francisco, Bragança Paulista, Brazil (F.B.M.P.); and Departments of Physiology (C.E.T., R.C.W.) and Pharmacology and Toxicology (H.A.T.), Georgia Regents University, Augusta, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cleber E. Teixeira
Department of Cell and Regenerative Biology, University of Wisconsin, Madison, Wisconsin (K.P.N.); Laboratory of Multidisciplinary Research, Universidade São Francisco, Bragança Paulista, Brazil (F.B.M.P.); and Departments of Physiology (C.E.T., R.C.W.) and Pharmacology and Toxicology (H.A.T.), Georgia Regents University, Augusta, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fernanda B. M. Priviero
Department of Cell and Regenerative Biology, University of Wisconsin, Madison, Wisconsin (K.P.N.); Laboratory of Multidisciplinary Research, Universidade São Francisco, Bragança Paulista, Brazil (F.B.M.P.); and Departments of Physiology (C.E.T., R.C.W.) and Pharmacology and Toxicology (H.A.T.), Georgia Regents University, Augusta, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haroldo A. Toque
Department of Cell and Regenerative Biology, University of Wisconsin, Madison, Wisconsin (K.P.N.); Laboratory of Multidisciplinary Research, Universidade São Francisco, Bragança Paulista, Brazil (F.B.M.P.); and Departments of Physiology (C.E.T., R.C.W.) and Pharmacology and Toxicology (H.A.T.), Georgia Regents University, Augusta, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Clinton Webb
Department of Cell and Regenerative Biology, University of Wisconsin, Madison, Wisconsin (K.P.N.); Laboratory of Multidisciplinary Research, Universidade São Francisco, Bragança Paulista, Brazil (F.B.M.P.); and Departments of Physiology (C.E.T., R.C.W.) and Pharmacology and Toxicology (H.A.T.), Georgia Regents University, Augusta, Georgia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Type 2 diabetes mellitus (DM2) and obesity are major risk factors for erectile dysfunction (ED). In diabetes, increased oxidative stress leads to decreased nitric oxide (NO) bioavailability, and diabetic patients appear to be less responsive to conventional therapy with phosphodiesterase type 5 inhibitors. We investigated whether the soluble guanylyl cyclase stimulator BAY 41-2272 (5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-4ylamine) is effective in improving impaired corpus cavernosum (CC) relaxation in obese DM2 mice by reducing oxidative stress. Adult db/db−/− mice or their lean db/+ littermates were used to assess vascular function, cGMP levels, antioxidant status, NADPH oxidase expression, and superoxide formation in the absence or presence of BAY 41-2272. Results showed that BAY 41-2272 (10−8 to 10−5 M) potently relaxed CC from db/+ or db/db−/− mice in a similar manner. BAY 41-2272 significantly enhanced both endothelium-dependent and nitrergic relaxation induced by electrical field stimulation (EFS), and improved the impaired relaxation to acetylcholine and EFS in the diabetic animals in a concentration-dependent manner (10−8 to 10−7 M). BAY 41-2272 increased cGMP levels and potentiated relaxation responses to exogenous NO in CC. Total antioxidant status was reduced in plasma and urine whereas expression of vascular NADPH oxidase subunits (gp91phox, p22phox, and p47phox) was increased in the CC of db/db−/− mice, suggesting a state of oxidative stress. These effects were prevented by BAY 41-2272 in a concentration-dependent manner. These results suggest that BAY 41-2272 improves CC relaxation in db/db−/− mice by increasing cGMP and augmenting antioxidant status, making this drug is a potential novel candidate to treat ED.

Footnotes

    • Received October 22, 2014.
    • Accepted March 4, 2015.
  • This work was supported by American Heart Association Scientific Development Grant [12SDG12080023] (to K.P.N.).

  • Dr. Cleber E. Teixeira, who helped design, perform, and interpret the experiments presented in this manuscript, unfortunately died in 2007 before the publication of this article, to which he was an essential contributor.

  • dx.doi.org/10.1124/jpet.114.220970.

  • Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 353 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 353, Issue 2
1 May 2015
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Beneficial Effect of the Soluble Guanylyl Cyclase Stimulator BAY 41-2272 on Impaired Penile Erection in db/db−/− Type II Diabetic and Obese Mice
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleDrug Discovery and Translational Medicine

Effect of BAY 41-2272 on Penile Erection in db/db−/− Mice

Kenia Pedrosa Nunes, Cleber E. Teixeira, Fernanda B. M. Priviero, Haroldo A. Toque and R. Clinton Webb
Journal of Pharmacology and Experimental Therapeutics May 1, 2015, 353 (2) 330-339; DOI: https://doi.org/10.1124/jpet.114.220970

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleDrug Discovery and Translational Medicine

Effect of BAY 41-2272 on Penile Erection in db/db−/− Mice

Kenia Pedrosa Nunes, Cleber E. Teixeira, Fernanda B. M. Priviero, Haroldo A. Toque and R. Clinton Webb
Journal of Pharmacology and Experimental Therapeutics May 1, 2015, 353 (2) 330-339; DOI: https://doi.org/10.1124/jpet.114.220970
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • SGS742 and Treatment of GHB Overdoses
  • Fate determination role of erythropoietin and romiplostim
  • Pharmacology of Antifentanyl mAb with Naloxone in Rats
Show more Drug Discovery and Translational Medicine

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics